Why the study?
Does the P2RY12 rs6809699 polymorphism influence antiplatelet response and resistance to clopidogrel in patients with coronary heart disease?
Does the P2RY12 rs6809699 polymorphism influence antiplatelet response and resistance to clopidogrel in patients with coronary heart disease?
The P2RY12 rs6809699 AA genotype may serve as an independent genetic marker for clopidogrel resistance and high on-treatment platelet activity in CHD patients.
May flag clopidogrel resistance beyond CYP2C19; hypothesis-generating and requires prospective validation before practice change.
Our data suggest that P2RY12 rs6809699 is associated with clopidogrel resistance in CHD patients. Meanwhile, the rs6809699 AA genotype can increase on-treatment platelet activity independent of CYP2C19 LOF polymorphisms.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: